{"id":"gp-ccrt","safety":{"commonSideEffects":[{"rate":null,"effect":"Hematologic toxicity (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Radiation dermatitis"}]},"_chembl":{"chemblId":"CHEMBL4297963","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This regimen combines gemcitabine and cisplatin chemotherapy agents with concurrent administration of chemotherapy during radiotherapy (CCRT). The chemotherapy drugs induce DNA damage and cell death, while concurrent radiation amplifies cytotoxic effects through radiosensitization. This multimodal approach is designed to improve local and systemic tumor control in solid malignancies.","oneSentence":"GP+CCRT is a combination treatment regimen pairing gemcitabine/cisplatin chemotherapy with concurrent chemoradiotherapy to enhance tumor control through synergistic cytotoxic and radiation effects.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:14:12.204Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Locally advanced solid tumors (specific indication under investigation in phase 3 trial)"}]},"trialDetails":[{"nctId":"NCT07362979","phase":"PHASE2","title":"Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-12","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":243},{"nctId":"NCT04833257","phase":"PHASE2","title":"Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2021-04-14","conditions":"Nasopharyngeal Carcinoma","enrollment":63},{"nctId":"NCT06605131","phase":"PHASE2","title":"GP Combined with Toripalimab Versus GP Induction Chemotherapy for Advanced Childhood Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-04-17","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":72},{"nctId":"NCT06712888","phase":"PHASE3","title":"Toripalimab Vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-02-17","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":466},{"nctId":"NCT03840421","phase":"PHASE3","title":"GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-04-03","conditions":"Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases","enrollment":468},{"nctId":"NCT05193617","phase":"PHASE2","title":"Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-01-20","conditions":"Nasopharyngeal Carcinoma","enrollment":104},{"nctId":"NCT06301165","phase":"PHASE2","title":"TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-03-19","conditions":"Nasopharyngeal Carcinoma","enrollment":162},{"nctId":"NCT06455410","phase":"PHASE2","title":"GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-06-18","conditions":"Nasopharyngeal Carcinoma","enrollment":216},{"nctId":"NCT05211232","phase":"PHASE3","title":"Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-06-10","conditions":"Nasopharyngeal Carcinoma","enrollment":450},{"nctId":"NCT05189028","phase":"PHASE3","title":"Study of Neoadjuvant Chemotherapy Versus Definite Concurrent Chemoradiotherapy for Locally Advanced Bulk Cervical Cancer","status":"UNKNOWN","sponsor":"Chuangzhen Chen","startDate":"2021-07-01","conditions":"Cervical Cancer, Neoadjuvant Chemotherapy","enrollment":290},{"nctId":"NCT06092957","phase":"PHASE3","title":"Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-10-09","conditions":"Nasopharyngeal Carcinoma, De-escalation Therapy","enrollment":504},{"nctId":"NCT03321539","phase":"PHASE3","title":"Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2017-10-30","conditions":"Nasopharyngeal Carcinoma","enrollment":216},{"nctId":"NCT05772208","phase":"PHASE3","title":"Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-01-01","conditions":"Nasopharyngeal Carcinoma","enrollment":459},{"nctId":"NCT05448885","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2021-09-01","conditions":"Nasopharyngeal Carcinoma","enrollment":50},{"nctId":"NCT04605562","phase":"PHASE2","title":"Umbrella Biomarker-Guided Therapy in NPC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-06","conditions":"Nasopharyngeal Carcinoma","enrollment":206},{"nctId":"NCT04447326","phase":"PHASE2","title":"Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2020-06","conditions":"Nasopharyngeal Carcinoma","enrollment":106},{"nctId":"NCT04414566","phase":"PHASE3","title":"Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2020-06-01","conditions":"Nasopharyngeal Carcinoma","enrollment":562},{"nctId":"NCT03604965","phase":"PHASE3","title":"GP Induction Chemotherapy us TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC","status":"UNKNOWN","sponsor":"Guiyang Medical University","startDate":"2018-07-21","conditions":"Locally Advanced Nasopharyngeal Carcinoma","enrollment":204}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Experimental group"],"phase":"phase_3","status":"active","brandName":"GP+CCRT","genericName":"GP+CCRT","companyName":"Guiyang Medical University","companyId":"guiyang-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GP+CCRT is a combination treatment regimen pairing gemcitabine/cisplatin chemotherapy with concurrent chemoradiotherapy to enhance tumor control through synergistic cytotoxic and radiation effects. Used for Locally advanced solid tumors (specific indication under investigation in phase 3 trial).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}